These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 21819369)

  • 1. Ten-year follow-up of basiliximab induction therapy for live-donor kidney transplant: a prospective randomized controlled study.
    Sheashaa HA; Bakr MA; Rashad RH; Ismail AM; Sobh MA; Ghoneim MA
    Exp Clin Transplant; 2011 Aug; 9(4):247-51. PubMed ID: 21819369
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term evaluation of basiliximab induction therapy in live donor kidney transplantation: a five-year prospective randomized study.
    Sheashaa HA; Bakr MA; Ismail AM; Gheith OE; El-dahshan KF; Sobh MA; Ghoneim MA
    Am J Nephrol; 2005; 25(3):221-5. PubMed ID: 15908741
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Basiliximab induction in renal transplantation: long-term outcome.
    Atlani M; Sharma RK; Gupta A
    Saudi J Kidney Dis Transpl; 2013 May; 24(3):473-9. PubMed ID: 23640617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Basiliximab induction therapy for live donor kidney transplantation: a long-term follow-up of prospective randomized controlled study.
    Sheashaa HA; Bakr MA; Ismail AM; Mahmoud KM; Sobh MA; Ghoneim MA
    Clin Exp Nephrol; 2008 Oct; 12(5):376-381. PubMed ID: 18327678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Basiliximab versus daclizumab combined with triple immunosuppression in deceased donor renal transplantation: a prospective, randomized study.
    Kandus A; Arnol M; Omahen K; Oblak M; Vidan-Jeras B; Kmetec A; Bren AF
    Transplantation; 2010 Apr; 89(8):1022-7. PubMed ID: 20075788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Basiliximab reduces the incidence of acute cellular rejection in live-related-donor kidney transplantation: a three-year prospective randomized trial.
    Sheashaa HA; Bakr MA; Ismail AM; Sobh MA; Ghoneim MA
    J Nephrol; 2003; 16(3):393-8. PubMed ID: 12832740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Usefulness of Tacrolimus without Basiliximab in Well-Matched Living-Donor Renal Transplant Recipients in Korea.
    Baek CH; Kim JH; Yu H; Shin E; Cho H; Kim H; Yang WS; Han DJ; Park SK
    Exp Clin Transplant; 2016 Aug; 14(4):389-93. PubMed ID: 27228054
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of thymoglobulin and basiliximab in kidney transplant patients at high risk for acute rejection and delayed graft function.
    Chen G; Gu J; Qiu J; Wang C; Fei J; Deng S; Li J; Huang G; Fu Q; Chen L
    Exp Clin Transplant; 2013 Aug; 11(4):310-4. PubMed ID: 23121641
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-thymocyte globulin versus basiliximab induction in renal transplant recipients: Long-term outcome.
    Kesiraju S; Paritala P; Rao Ch UM; Athmakuri SM; Reddy VS; Sahariah S
    Saudi J Kidney Dis Transpl; 2014 Jan; 25(1):9-15. PubMed ID: 24434376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of basiliximab in pediatric renal transplant patients receiving cyclosporine, mycophenolate mofetil, and steroids.
    Offner G; Toenshoff B; Höcker B; Krauss M; Bulla M; Cochat P; Fehrenbach H; Fischer W; Foulard M; Hoppe B; Hoyer PF; Jungraithmayr TC; Klaus G; Latta K; Leichter H; Mihatsch MJ; Misselwitz J; Montoya C; Müller-Wiefel DE; Neuhaus TJ; Pape L; Querfeld U; Plank C; Schwarke D; Wygoda S; Zimmerhackl LB
    Transplantation; 2008 Nov; 86(9):1241-8. PubMed ID: 19005406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term safety and efficacy of antithymocyte globulin induction: use of integrated national registry data to achieve ten-year follow-up of 10-10 Study participants.
    Lentine KL; Schnitzler MA; Xiao H; Brennan DC
    Trials; 2015 Aug; 16():365. PubMed ID: 26285695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved efficacy of basiliximab over antilymphocyte globulin induction therapy in paediatric renal transplantation.
    Clark G; Walsh G; Deshpande P; Koffman G
    Nephrol Dial Transplant; 2002 Jul; 17(7):1304-9. PubMed ID: 12105256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimizing Immunosuppressive Regimens Among Living-Donor Renal Transplant Recipients.
    Bakr MA; Nagib AM; Gheith OA; Hamdy AF; Refaie AF; Donia AF; Neamatalla AH; Eldahshan KF; Denewar AA; Abbas MH; Mostafa AI; Ghoneim MA
    Exp Clin Transplant; 2017 Feb; 15(Suppl 1):16-23. PubMed ID: 28260425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tacrolimus-based, steroid-free regimens in renal transplantation: 3-year follow-up of the ATLAS trial.
    Krämer BK; Klinger M; Vítko Š; Glyda M; Midtvedt K; Stefoni S; Citterio F; Pietruck F; Squifflet JP; Segoloni G; Krüger B; Sperschneider H; Banas B; Bäckman L; Weber M; Carmellini M; Perner F; Claesson K; Marcinkowski W; Ostrowski M; Senatorski G; Nordström J; Salmela K
    Transplantation; 2012 Sep; 94(5):492-8. PubMed ID: 22858806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Steroid avoidance reduce the cost of morbidities after live-donor renal allotransplants: a prospective, randomized, controlled study.
    Gheith OA; Nematalla AH; Bakr MA; Refaie A; Shokeir AA; Ghoneim MA
    Exp Clin Transplant; 2011 Apr; 9(2):121-7. PubMed ID: 21453230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early steroid withdrawal protocol with basiliximab, cyclosporine and mycophenolate mofetil in renal-transplant recipients.
    Kato Y; Tojimbara T; Iwadoh K; Koyama I; Nanmoku K; Kai K; Sannomiya A; Nakajima I; Fuchinoue S; Teraoka S
    Int Immunopharmacol; 2006 Dec; 6(13-14):1984-92. PubMed ID: 17161352
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of basiliximab on renal allograft rejection within 1 year after transplantation.
    Lee BM; Oh CK; Jin SH; Kim JH; Kim SJ; Kim H; Shin GT
    Transplant Proc; 2006 Sep; 38(7):2025-8. PubMed ID: 16979988
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rabbit antithymocyte globulin compared with basiliximab in kidney transplantation: a single-center study.
    Kim JM; Jang HR; Kwon CH; Huh WS; Kim GS; Kim SJ; Joh JW; Oh HY
    Transplant Proc; 2012 Jan; 44(1):167-70. PubMed ID: 22310606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Steroid-avoidance immunosuppression regimen in live-donor renal allotransplant recipients: a prospective, randomized, controlled study.
    Nematalla AH; Bakr MA; Gheith OA; Elagroudy AE; Elshahawy el-M; Aghoneim M
    Exp Clin Transplant; 2007 Dec; 5(2):673-9. PubMed ID: 18194120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proteinuria among primarily sirolimus treated live-donor renal transplant recipients' long-term experience.
    Hamdy AF; Bakr MA; Ghoneim MA
    Exp Clin Transplant; 2010 Dec; 8(4):283-91. PubMed ID: 21143093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.